NEWSROOM

Healthcare

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

Aug 14, 2025

POMPANO BEACH, FL, August 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Appointed Brandon Poe as Chief Financial Officer, a seasoned financial executive with experience across the...

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

Aug 14, 2025

Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem’s financial team POMPANO BEACH, FL, August 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief...

American Shared Hospital Services Reports Second Quarter 2025 Financial Results

American Shared Hospital Services Reports Second Quarter 2025 Financial Results

Aug 13, 2025

Total Revenue Increased 16% Sequentially Conference Call Scheduled for 1:00 PM ET Today SAN FRANCISCO, CA, August 13, 2025 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced financial results for the second quarter ended June 30, 2025. Key Financial Highlights Q2...

SS Innovations Reports Second Quarter 2025 Financial Results

SS Innovations Reports Second Quarter 2025 Financial Results

Aug 7, 2025

Record Quarterly Revenue of $10.0 Million Driven by Higher SSi Mantra 3 Unit Sales Gross Profit More than Tripled, Driven by Gross Margin Expansion and Revenue Growth Fort Lauderdale, FL. August 7, 2025 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited...

American Shared Hospital Services Reports Second Quarter 2025 Financial Results

American Shared Hospital Services Announces Second Quarter Financial Results Conference Call

Aug 6, 2025

Call Scheduled for August 13th at 1:00 PM ET SAN FRANCISCO, August 6, 2025 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its second quarter 2025 financial results on August 13th at 1:00 pm ET. The...

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

Jul 30, 2025

NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 - PRISM MediaWire - Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041. This patent underpins one of the Company’s key pipeline assets, a modified stilbenoid, and importantly provides the Company with exclusivity to particular compounds per se, formulations containing a number of drug candidates, and...

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025

Jul 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 29, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will release its second quarter 2025 financial results on Thursday, August 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature a review of second quarter...

SS Innovations Reports Second Quarter 2025 Financial Results

SS Innovations Announces Completion of World’s First Intercontinental Robotic Cardiac Telesurgery

Jul 22, 2025

Performed by Dr. Sudhir Srivastava utilizing the Company’s SSi Mantra 3 surgical robotic system Remotely conducted from IRCAD in Strasbourg, France at an unprecedented distance of more than 4,000 miles to the operating room at SAIMS in Indore, India Fort Lauderdale, FL, July 22, 2025 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and...

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes

Jul 17, 2025

The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the Centers for Medicare and Medicaid Services (“CMS”) release of the...

SS Innovations Reports Second Quarter 2025 Financial Results

SS Innovations Surpasses Milestone of 100 Installations of the SSi Mantra Surgical Robotic System

Jul 15, 2025

Continuing strong procedure growth, including an upsurge in telesurgeries Fort Lauderdale, FL, July 15, 2025 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company has installed more than 100 SSi Mantra surgical robotic systems in India and six other countries. To...

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET

Jul 10, 2025

Jason Matuszewski, Chairman and CEO, to present BioStem’s current position in the chronic wound care market and key opportunities for growth POMPANO BEACH, Fla., July 10, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’s Chairman and CEO, will present at the Advanced Wound Care...

SS Innovations Reports Second Quarter 2025 Financial Results

SS Innovations Announces Completion of World’s First Robotic Telesurgery for Weight Loss with the Company’s SSi Mantra 3 Surgical Robotic System

Jul 10, 2025

Led by Dr. Mohit Bhandari, a pioneer in bariatric surgery and President of the Institute of Research Against Digestive Cancer (IRCAD) India, the surgery was remotely performed at a distance of 560 miles and executed on-site at Mohak Bariatric & Robotic Surgery Centre in Indore, India. Two advanced One-Anastomosis Gastric Bypass (OAGB) procedures were performed via telesurgery, with zero perceptible lag, flawless precision, and seamless robotic control using the SSI Mantra 3 system. Fort...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Jul 7, 2025

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time Broomfield, CO, July 7, 2025 - PRISM MediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Jun 25, 2025

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Jun 24, 2025

Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think Tank BROOMFIELD, Colo., June 24, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the upcoming State of...

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers

Jun 23, 2025

Head-to-head study comparing BioREtain®- processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 POMPANO BEACH, Fla., June 23, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today...

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award Winner

Jun 17, 2025

Award celebrates bold leaders shaping the future through the world’s most ground-breaking companies POMPANO BEACH, Fla., June 17, 2025 - PRISM MediaWire - Ernst & Young LLP (EY US) announced that Jason Matuszewski, CEO and Chairman of the Board of BioStem Technologies (OTC: BSEM), was named an Entrepreneur Of The Year 2025 Florida Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. For 40 years, EY US...

SS Innovations Reports Second Quarter 2025 Financial Results

SS Innovations Announces Successful Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company’s SSi Mantra 3 Surgical Robotic System

Jun 16, 2025

Surgery performed by Dr. Juan Zuniga at Interhospital in Guayaquil, Ecuador PR Audio: Fort Lauderdale, FL, June 16, 2025 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the first robotic cardiac surgery in the Americas and Western Hemisphere has been successfully performed...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

Jun 10, 2025

UHealth — University of Miami Health System and the University of Miami Miller School of Medicine provide world-class research and renowned clinical expertise in spine surgery CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., June 10,...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

Jun 3, 2025

Upon SEC approval of the amended Form 10, BioStem expects to advance its uplisting to Nasdaq POMPANO BEACH, Fla., June 3, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today provides an update on the Company’s Form 10 registration statement and SEC review process. BioStem believes it has favorably...

SS Innovations Reports Second Quarter 2025 Financial Results

SS Innovations to Ring the Nasdaq Opening Bell on Tuesday, June 3, 2025

Jun 2, 2025

Fort Lauderdale, FL, June 2, 2025 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company will ring the opening bell at the Nasdaq MarketSite in New York City on Tuesday, June 3, 2025. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025

POMPANO BEACH, Fla., May 29, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami. Jason Matuszewski, the Company’s CEO, will participate in a fireside chat and will be available for...

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

May 28, 2025

Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease JACKSON CENTER, Pa., May 28, 2025 - PRISM MediaWire - Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

BioStem Announces Notice of Allowance for Three New U.S. Patent Applications

May 28, 2025

Expanding patent portfolio reinforces the Company’s commitment to wound care innovation, with 55 issued patents and 52 pending applications POMPANO BEACH, Fla., May 28, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance...

Catheter Precision, Inc. Receives CE Mark for LockeT

Catheter Precision, Inc. Receives CE Mark for LockeT

May 27, 2025

Opens Multi-Billion Market Opportunity for the Company First Order for 100 Units Received FORT MILL, S.C., May 27, 2025 - PRISM MediaWire - Catheter Precision, Inc. (NYSE American: VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received CE Mark approval for LockeT, the latest advanced vascular closure device. Receipt of the CE Mark indicates compliance with European Union (EU)...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist

May 22, 2025

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future POMPANO BEACH, Fla., May 22, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, CEO of BioStem is an Ernst & Young LLP (EY US) finalist for the prestigious Entrepreneur...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 20, 2025

USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 - PRISM MediaWire - Aclarion, Inc.,...

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

May 15, 2025

Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “we,” “our,” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from the first two dose cohorts of its ongoing...

American Shared Hospital Services Reports First Quarter 2025 Financial Results

American Shared Hospital Services Reports First Quarter 2025 Financial Results

May 15, 2025

Reports 17% Year over Year First Quarter Revenue Growth Conference Call Scheduled for 12:00 PM ET Today SAN FRANCISCO, CA, May 15, 2025 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced financial results for the first quarter ended March 31, 2025. Key Financial...

American Shared Hospital Services Reports First Quarter 2025 Financial Results

American Shared Hospital Services Announces First Quarter Financial Results Conference Call

May 12, 2025

Call Scheduled for May 15th at 12:00 PM ET SAN FRANCISCO, May 12, 2025 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its first quarter 2025 financial results on May 15th at 12:00 pm ET. The first...